Search
Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
Aug 1413 min read
The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers
The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment
Aug 1212 min read
From Hospital Pharmacy to the MHRA: How Jas Changed Her Career in Regulatory Affairs
Part of the Entry to Regulatory Success Stories Series Jas was a hospital pharmacist who felt stuck — until she discovered regulatory affairs. Here's how she made the leap to the MHRA, and what her journey can teach you. She Knew Medicines Inside Out. But the Industry Didn't Know Her. Jas had built her career in hospital pharmacy. Day after day, she worked at the intersection of medicines, patients, and clinical decision-making — reviewing prescriptions, counselling patie
Jun 198 min read